Personalis®

Board Members

Pioneering Genome-Guided Medicine

Jonathan MacQuitty, PhD | Personalis Chairman

Jonathan MacQuitty, former partner at Abingworth, has more than 15 years of operational experience in senior executive roles in life science companies.
Jonathan MacQuitty, former partner at Abingworth, has more than 15 years of operational experience in life science companies, and 12 years of venture capital experience. His directorships have included Adiana, Dicerna, Entelos, Guava, Gynesonics, Iconix, Labcyte, ParAllele BioScience, Personalis, SFJ Pharma and Sunesis Pharmaceuticals. He joined Abingworth in 1999 as President and Director of the company’s US subsidiary, Abingworth Management Inc., and is based at the firm’s offices in Menlo Park, California. Before joining Abingworth he was an adviser to a Japanese venture capital firm. Between 1988 and 1997 he was CEO of GenPharm International, a biotech company in which Abingworth invested. Before this he held business development positions at Genencor and Genentech. He has served on the Board of the Biotechnology Industry Organisation (BIO). Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex, and an MBA from Stanford University. Jonathan is now the CEO of Forty Seven, Inc, an immuno-oncology company based in Palo Alto, CA.

Pat Balthrop | Recently retired CEO of Luminex, Inc.

Patrick Balthrop is the founding principal of Apalachee Ventures. He has over 30 years of experience building, growing and optimizing businesses in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools and medical devices.
Patrick Balthrop is the founding principal of Apalachee Ventures. He has over 30 years of experience building, growing and optimizing businesses in the healthcare sector, particularly in the life sciences segments of diagnostics, life science tools and medical devices.

Previously, Pat was CEO, President and Director of Luminex Corporation, a publicly-traded diagnostics, tools and devices company. During his ten year tenure as CEO, Luminex increased sales more than eight-fold, transitioned from a loss position to segment-leading levels of profitability, made several strategic acquisitions and introduced numerous new products.

Prior to Luminex, Balthrop was President of Fisher Healthcare from 2002 to 2004. He also had a 20 year career at Abbott from 1981 to 2002, where he ran the company’s worldwide commercial operation, was the first head of Abbott Vascular, ran several R&D programs and was GM of the Far East Area, among other accomplishments.

In addition to his board position at Personalis, Balthrop is a director of Oxford Immunotec Global, a high growth diagnostics company focused on the development and commercialization of proprietary diagnostic tests for the management of immune-related conditions.  Balthrop is also a director of NextGxDx, a private healthcare informatics company that is harnessing the power of the clinical value of the human genome.

Balthrop has an MBA from the Kellogg School of management at Northwestern University, and a BS in Biology from Spring Hill College.

Ken Ludlum | Chairman, Personalis Audit Committee and Chief Financial Officer of CareDx, Inc.

Ken Ludlum, Chairman of the Audit Committee at Personalis, has 25 years of experience as a Chief Financial Officer of medical device, biotechnology and molecular diagnostic companies. He has served as Audit Committee Chair of three publicly traded medical companies, and has handled IPOs, acquisitions, buyouts and fast revenue growth as both CFO and as a Board member.
Ken Ludlum is Chairman of the Audit Committee at Personalis and serves as Chief Financial Officer of CareDx, Inc., a molecular diagnostics company. Ken led the initial public offering of CareDx in 2014. Prior to that Ken has been the CFO or CEO of medical device companies and biotechnology companies and has handled several other IPOs, acquisitions or buyouts. He has served as Chairman of Audit Committees for two other publicly traded companies and several private companies, including public companies that went through initial public offerings, that were acquired, or that grew 10x in revenues and market value over the years.

Prior to 25 years in operating positions, he spent 10 years as an investment banker, primarily with Montgomery Securities. He holds a Bachelor of Science degree from Lehigh University and an MBA from Columbia Business School.

Vincent Miles | Partner, Abingworth

Vincent Miles, Partner, Abingworth has more than 30 years of management experience in the biotechnology industry, including early work at Dana Farber Cancer Research Institute. He has 15 years experience in Business Development with BioPharmaceutical companies (Ribogene, Millenium, Alnylam).
Vincent has more than 30 years of management experience in the biotechnology industry, including over 15 years in Business Development in BioPharmaceuticals. He identifies and invests in new businesses and supports portfolio companies. Vincent is on the boards of Dynex Technologies, Hydra Biosciences, Magellan Diagnostics and Personalis, and has also served on the boards of Chiasma, Dicerna Pharmaceuticals and PrimeraDx. Before joining Abingworth he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company).

Previously, Vincent was at Millennium Pharmaceuticals  where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International. He has a BSc in Biochemistry and a PhD in Molecular Biology from University College London.

Chris Schaepe | Founder, Lightspeed Venture Partners

Chris Schaepe is a founder of Lightspeed Venture Partners, covering infrastructure technologies and services. His early experience includes positions with IBM and Goldman Sachs.
Chris Schaepe is a founder of Lightspeed Venture Partners, covering infrastructure technologies and services. He has twenty years of venture capital experience and four years of operating experience. Prior to Lightspeed, Chris served in corporate finance and capital markets roles at Goldman, Sachs & Co. Previously, he was a software engineer at IBM. Chris has frequently been named to the Forbes Midas List of top venture capital investors. He serves on a number of private company boards and public boards including Riverbed Technology. Chris holds BS and MS degrees in Computer Science and Electrical Engineering from MIT and an MBA from Stanford University.

John West | Chief Executive Officer

John West, founder and CEO of Personalis, Inc., has been involved in DNA sequencing and interpretation since 1982. He has held senior executive positions at Applied Biosystems, Solexa and Illumina.
Personalis’ CEO, John West, began his involvement in DNA sequencing, and DNA sequence interpretation, in 1982. In the 1980’s, he led the development of an automated DNA sequencing system based on pattern recognition from autoradiographs, and licensed software from the lab of Roger Staden at the MRC LMB in Cambridge, UK for sequence assembly and analysis. In the 1990’s, Mr. West was General Manager and subsequently President of Princeton Instruments, a company focused on low light scientific imaging. This technology was used in a number of fluorescent automated DNA sequencing developments. In 2001, Mr. West joined then market leader Applied Biosystems, as Vice President of Genetic Analysis. He was subsequently promoted to VP, DNA Platforms. While at Applied Biosystems, Mr. West’s group introduced the model 3730xl Genetic Analyzer. This product became the mainstay of almost every major genome center in the world.In 2004, Mr. West moved to be CEO of Solexa Ltd, a venture capital backed UK company focused primarily on single-molecule DNA sequencing. Mr. West realized that the company’s recent acquisition of DNA cluster technology could be transformative. In 2005 he led Solexa’s reverse merger into US-based and Nasdaq-listed Lynx Therapeutics, and led two PIPE financings totaling almost $100M. The company introduced its first system in mid-2006. Mr. West negotiated the January 2007 acquisition of Solexa by Illumina, Inc for approximately $600M, and stayed as VP of the DNA sequencing business there into 2008. During this time, Illumina became the world leader in next generation DNA sequencing.

From 2009 through mid-2011, Mr. West served as CEO of ViaCyte, Inc, a company leveraging stem cell technology to develop a diabetes cell therapy.

In late 2009, Mr. West’s family became the first healthy family of four have their genomes sequenced. Their experience working with the Stanford team on genome interpretation led to the foundation of Personalis.

Mr. West received BS and MS engineering degrees from MIT, and earned an MBA from the University of Pennsylvania’s Wharton School of Business.